InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: petemantx post# 340327

Sunday, 01/17/2021 2:35:15 PM

Sunday, January 17, 2021 2:35:15 PM

Post# of 403568
I agree petemantx... If Brilacidin proves a covid killer in human trials the sp could be substantial. We are going to find out soon.

They cannot escape reality...

Go Leo & IPIX!

So true, hard to believe expectations by some are so low and why.

If (no, when) Brilacidin becomes the gold standard for CV19 treatment and shows it can stop deaths even in severe cases the entire world will be clamoring for the drug. Rems.... is a POS treatment and yet has garnered Billions. Brilacidin revenues should dwarf it.

And yet some think only $5/share???

Now parlay up the CV19 results to possibly most every virus the world faces in today's world? Revenues again soaring and most likely, like CV19, IPIX won't have to partner these products with a BP (though most likely they will).

Add in respiratory indications ($70B/yr revs), GI tract indications ($50+B yearly revs), dermatology related indications, anti inflammatory indications (COPD, Athsma, Bronchitis) at $75+B/yr revenues, possible kidney, brain (tests showed possible encephalitic improvements), and a whole host of other applications and the numbers get crazy large.

Some keep saying long shot, long shot, long shot yet Brilacidin has pretty much shown in prior trials it is a safe product and to date it appears to be the class leader treatment for the indications it has been tested as to efficacy.

Nebulizer and inhalant delivery systems currently being created and that could lead to a whole new set of uses.

I think we are holding maybe the most prolific across the medical spectrum drug the world has seen to date.

This is no $5 play. LOL


Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating
COVID-19

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News